Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine (notably candidate SBT-101) is a virus-like particle (VLP) vaccine developed by SpyBiotech in collaboration with the Serum Institute of India. The vaccine utilizes a "plug-and-display" strategy using SpyBiotech's proprietary SpyTag/SpyCatcher protein ligation technology. In this system, the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is covalently conjugated to hepatitis B surface antigen (HBsAg) VLPs. This multivalent presentation of the RBD is designed to mimic the repetitive structure of a virus, thereby enhancing B-cell activation and the induction of high-titer neutralizing antibodies. The use of the HBsAg VLP scaffold leverages a platform with a long history of safety and established large-scale manufacturing processes. Clinical development, including Phase I/II trials in Australia (managed by Accelagen), has focused on evaluating the safety and immunogenicity of the vaccine, often formulated with an aluminum-based adjuvant.
- Brand names
- COVIVAXX
- Other names
- RBD-HBsAg VLP vaccineSpyBiotech COVID-19 vaccineRBD SARS-CoV-2 HBsAg VLP
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine.